<DOC>
	<DOC>NCT02590263</DOC>
	<brief_summary>This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma.</brief_summary>
	<brief_title>Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Japanese participants with WHO grade III or IV malignant glioma in Phase 1 portion or WHO grade IV GBM in Phase 2 portion 70 or above on Karnofsky Performance Status in Arm A of Phase 1 portion and Phase 2 portion 80 or above on Karnofsky Performance Status in Arm B of Phase 1 portion Adequate bone marrow function Recurrent malignant glioma per RANO criteria in Arm A of Phase 1 portion and Phase 2 portion Histologically proven newly diagnosed malignant glioma in Arm B of Phase 1 portion Participants must have confirmed EGFR amplification by central lab in Phase 2 portion Anticancer treatment 28 days prior to study Day 1 for Arm A of Phase 1 portion and Phase 2 portion (except temozolomide therapy for newly diagnosed treatment for Phase 2 portion) Anticancer treatment prior to study Day 1 for Arm B of Phase 1 portion Participant has received prior treatment with bevacizumab, for recurrent glioblastoma, EGFR therapy or has secondary grade IV GBM in Phase 2 portion Participant has a history of major immunologic reaction to any Immunoglobulin G containing agents or component of ABT414.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>WHO grade III</keyword>
	<keyword>WHO grade IV</keyword>
</DOC>